Alkermes (ALKS) Gets a Buy Rating from Credit Suisse

By Ryan Adsit

Credit Suisse analyst Vamil Divan maintained a Buy rating on Alkermes (NASDAQ: ALKS) yesterday and set a price target of $47. The company’s shares closed yesterday at $39.80, close to its 52-week low of $37.01.

According to, Divan is a 1-star analyst with an average return of -2.6% and a 43.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Merck & Company.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $52.83 average price target, a 32.7% upside from current levels. In a report issued on October 23, Cowen & Co. also maintained a Buy rating on the stock with a $58 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $71.22 and a one-year low of $37.01. Currently, Alkermes has an average volume of 652K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. It operates through the following geographical segments: U.S., Ireland, Rest of the World, and Other.